Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0095 | 0.7758 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0095 | 0.7758 | 1 |
Schistosoma mansoni | kinase | 0.0048 | 0.3578 | 0.4613 |
Echinococcus multilocularis | tar DNA binding protein | 0.0065 | 0.5052 | 0.6513 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.0902 | 0.1163 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0018 | 0.0902 | 0.1163 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0018 | 0.0902 | 1 |
Trypanosoma brucei | polo-like protein kinase | 0.0095 | 0.7758 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0047 | 0.3466 | 0.4468 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0095 | 0.7758 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0018 | 0.0902 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.012 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0065 | 0.5052 | 0.6513 |
Loa Loa (eye worm) | RNA binding protein | 0.0065 | 0.5052 | 0.4561 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0095 | 0.7758 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0047 | 0.3466 | 0.4468 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0018 | 0.0902 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Brugia malayi | RNA binding protein | 0.0065 | 0.5052 | 0.4561 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.5052 | 0.6513 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0018 | 0.0902 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.5052 | 0.6513 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.0902 | 0.1163 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0095 | 0.7758 | 0.7535 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.0902 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0.0902 | 0.1163 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.5052 | 0.6513 |
Brugia malayi | TAR-binding protein | 0.0065 | 0.5052 | 0.4561 |
Brugia malayi | serine/threonine-protein kinase plk-2 | 0.0095 | 0.7758 | 0.7535 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0095 | 0.7758 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0.0902 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0065 | 0.5052 | 0.4561 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.5052 | 0.6513 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0095 | 0.7758 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0065 | 0.5052 | 0.4561 |
Schistosoma mansoni | ap endonuclease | 0.0018 | 0.0902 | 0.1163 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0065 | 0.5052 | 0.4561 |
Giardia lamblia | Kinase, PLK | 0.0095 | 0.7758 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.7758 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0018 | 0.0902 | 0.1163 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0018 | 0.0902 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0095 | 0.7758 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.5052 | 0.6513 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.0008 | 0 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0095 | 0.7758 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.012 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 0 | Activity against caspase-mediated PARP cleavage in human DLD1 cells at 1 uM after 48 hrs by Western blot analysis | ChEMBL. | 16784854 |
Activity (functional) | 0 | Activity against DNA laddering in DLD1 cells at 1 uM after 48 hrs | ChEMBL. | 16784854 |
EC50 (functional) | = 270 nM | Induction of apoptosis in human DLD1 cells assessed as activation of caspases by HTS assay | ChEMBL. | 16784854 |
EC50 (functional) | = 270 nM | Induction of apoptosis in human DLD1 cells assessed as activation of caspases by HTS assay | ChEMBL. | 16784854 |
GI50 (functional) | = 229 nM | Growth inhibition of human DLD1 cells | ChEMBL. | 16784854 |
GI50 (functional) | = 229 nM | Growth inhibition of human DLD1 cells | ChEMBL. | 16784854 |
Inhibition (functional) | = 21 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 50 mg/kg, ip, qd | ChEMBL. | 16784854 |
Inhibition (functional) | = 21 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 50 mg/kg, ip, qd | ChEMBL. | 16784854 |
Inhibition (functional) | = 38 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 100 mg/kg, ip, qd | ChEMBL. | 16784854 |
Inhibition (functional) | = 38 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 100 mg/kg, ip, qd | ChEMBL. | 16784854 |
Inhibition (functional) | = 63 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 50 mg/kg, ip, bid | ChEMBL. | 16784854 |
Inhibition (functional) | = 63 % | Inhibition of tumor growth in BALB/c nude mouse implanted with DLD1 cells at 50 mg/kg, ip, bid | ChEMBL. | 16784854 |
Solubility | = 44 uM | Solubility of the compound | ChEMBL. | 16784854 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 16784854 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.